CTCF and invasive breast carcinoma: Since IL6 expression drives resistance to anticancer therapy in BrCa [30,53,54], we generated a Tamoxifen-resistant cell line that, as well as MDA-MB-231 cells, exhibited higher IL6 expression and no deposition of CTCF over the IL6 promoter.